There are a wide variety of disfiguring dermatological conditions whose pathologic substrate is represented by the unwanted deposition of collagen from dermal fibroblasts. Pirfenidone has demonstrated efficiency in the treatment of disordered collagen production when applied topically. Due to a similar mechanism of action, we also hypothesize that a similar medication, nintedanib, might have similar applications. We also propose that a liposomal technology may assist in the penetration of nintedanib and enhance its clinical effects.
CITATION STYLE
Cristodor, P. L., Nechifor, A., Fotea, S., Nadasdy, T., Bahloul, Y., Nicolescu, A. C., & Tatu, A. L. (2022). New Antifibroblastic Medication in Dermatology: Could Nintedanib Treat Scarring? International Journal of General Medicine, 15, 7169–7172. https://doi.org/10.2147/IJGM.S377073
Mendeley helps you to discover research relevant for your work.